In addition, there is compelling evidence that binding of the neurotoxic β-amyloid peptide to CAT decreases its activity [176], a phenomenon that may explain why CAT activity is reduced in the brain of Alzheimer’s disease patients [177]. This evidence concerns the gene CAT and Alzheimer disease.